Lebwohl David's Form 4 filing
Intellia Therapeutics, Inc. (NTLA) · filed Sep 23, 2021
- Accession no.
- 0001209191-21-057475
- Filed
- Sep 23, 2021
- Trade date
- Sep 21, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $359.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lebwohl DavidCIK 0001810882 | Officer (EVP, Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 21, 2021 | Common Stock | MOption exerciseAcquired | +2,400 | $12.62 | +$30,288 | 3,191 | Direct | |
| Sep 21, 2021 | Common Stock | SSaleDisposed | −2,400 | $149.81 | −$359,544 | 791 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 21, 2021 | Common Stock | MOption exerciseDisposed | −2,400 | $0.00 | $0 | 192,800 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.